You just read:

S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.

News provided by

Joseph F. Finn, Jr., C.P.A.

08 Nov, 2011, 22:12 GMT